Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexamethasone implant + ranibizumab
- Development stage
- Unknown
- Lead developer
- Allergan
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Ophthalmic, Intravitreal
01
Overview
Dexamethasone implant + ranibizumab refers to a therapeutic regimen or comparative study involving two established ophthalmic agents for the treatment of refractory diabetic macular edema (DME). The dexamethasone intravitreal implant (Ozurdex) is a biodegradable, sustained-release formulation of a potent synthetic glucocorticoid that reduces inflammation, vascular permeability, and the production of inflammatory cytokines by activating the glucocorticoid receptor. Ranibizumab (Lucentis) is a recombinant humanized monoclonal antibody fragment (Fab) that binds to and inhibits vascular endothelial growth factor A (VEGF-A), thereby preventing choroidal neovascularization and reducing macular edema. This specific combination or switch protocol is being investigated by Saglik Bilimleri Universitesi in patients who have shown an inadequate response to prior anti-VEGF therapy (specifically bevacizumab), aiming to evaluate the efficacy of switching to either a corticosteroid implant or a different anti-VEGF agent.
- Brand names
- OzurdexLucentis
- Other names
- dexamethasone intravitreal implantranibizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on dexamethasone implant + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexamethasone implant + ranibizumab.